BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Oili Halonen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Oili Halonen

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 8 December 2023 at 3.30 p.m. (EET)

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Oili Halonen

____________________________________________

Person subject to the notification requirement
Name: Halonen Oili
Position: Closely associated person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Halonen Jarmo
Position: Member of the Board
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20231208124156_4

____________________________________________

Transaction date: 2023-12-07
Venue not applicable
Instrument type: SHARE
ISIN: FI4000260583
Nature of the transaction: SUBSCRIPTION

Transaction details
(1): Volume: 2,475 Unit price: 0.4 EUR

Aggregated transactions
(1): Volume: 2,475 Volume weighted average price: 0.4 EUR

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
[email protected]

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
[email protected]

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi


Nyheter om BBS-Bioactive Bone

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien BBS-Bioactive Bone

Senaste nytt